Medexus Pharmaceuticals (TSE:MDP) Upgraded to Strong-Buy at Ventum Cap Mkts

Medexus Pharmaceuticals (TSE:MDP) was upgraded by stock analysts at Ventum Cap Mkts to a “strong-buy” rating in a research note issued on Wednesday, Zacks.com reports.

Medexus Pharmaceuticals Stock Performance

TSE:MDP opened at C$1.74 on Wednesday. The stock’s fifty day moving average is C$1.67 and its 200 day moving average is C$1.87. Medexus Pharmaceuticals has a fifty-two week low of C$1.30 and a fifty-two week high of C$3.53. The firm has a market capitalization of C$42.56 million, a PE ratio of 4.35 and a beta of 1.82.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.